ERBB2 and breast carcinoma: In one study, after multiple exposure cycles to an anti-HER2 trastuzumab-maytansinoid ADC that was structurally similar to ado-trastuzumab emtansine resulted in breast cancer cell lines becoming resistant to ado-trastuzumab emtansine.